The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Practice Guidelines for the Management of Patients with Blastomycosis
Abstract
Guidelines for the treatment of blastomycosis are presented; these guidelines are the consensus opinion of an expert panel representing the National Institute of Allergy and Infectious Diseases Mycoses Study Group and the Infectious Diseases Society of America. The clinical spectrum of blastomycosis is varied, including asymptomatic infection, acute or chronic pneumonia, and extrapulmonary disease. Most patients with blastomycosis will require therapy. Spontaneous cures may occur in some immunocompetent individuals with acute pulmonary blastomycosis. Thus, in a case of disease limited to the lungs, cure may have occurred before the diagnosis is made and without treatment; such a patient should be followed up closely for evidence of disease progression or dissemination. In contrast, all patients who are immunocompromised, have progressive pulmonary disease, or have extrapulmonary disease must be treated. Treatment options include amphotericin B, ketoconazole, itraconazole, and fluconazole. Amphotericin B is the treatment of choice for patients who are immunocompromised, have life-threatening or central nervous system (CNS) disease, or for whom azole treatment has failed. In addition, amphotericin B is the only drug approved for treating blastomycosis in pregnant women. The azoles are an equally effective and less toxic alternative to amphotericin B for treating immunocompetent patients with mild to moderate pulmonary or extrapulmonary disease, excluding CNS disease. Although there are no comparative trials, itraconazole appears more efficacious than either ketoconazole or fluconazole. Thus, itraconazole is the initial treatment of choice for non-life-threatening non-CNS blastomycosis. Blastomycosis is the systemic pyogranulomatous disease caused by the thermally dimorphic fungus Blastomyces dermatitidis. Like histoplasmosis and coccidioidomycosis, this disease occurs most commonly in defined geographic regions, hence its designation as an endemic mycosis. In North America, blastomycosis usually occurs in the southeastern and south central states that border the Mississippi and Ohio Rivers, the midwestern states and Canadian provinces bordering the Great Lakes, and a small area of New York and Canada adjacent to the St. Lawrence River [1]. Within these regions of endemicity, several studies have documented the presence of areas of hyperendemicity where the rate of blastomycosis is unusually high [1]. Point-source outbreaks have been associated with occupational and recreational activities, frequently along streams or rivers, which result in exposure to moist soil enriched with decaying vegetation [2, 3]. Initial infection results from inhalation of conidia into the lungs, although primary cutaneous blastomycosis has infrequently been reported after dog bites and accidental inoculation in the laboratory or at autopsy. The clinical spectrum of blastomycosis is varied, including asymptomatic infection, acute or chronic pneumonia, and disseminated disease [4]. As defined in point-source epidemics, asymptomatic infection occurs in at least 50% of infected persons, which supports the hypothesis that some have natural resistance [2]. Symptomatic disease develops after an incubation period of 30–45 days. Acute pulmonary blastomycosis mimics influenza or bacterial pneumonia. Spontaneous cures of symptomatic acute infection have been well documented, but the frequency of such cures has not been clearly defined [5]. Most patients diagnosed with blastomycosis have the indolent onset of chronic pneumonia. The clinical manifestations are indistinguishable from tuberculosis, other fungal infections, and cancer. Alveolar infiltrates, mass lesions that mimic bronchogenic carcinoma, and fibronodular interstitial infiltrates are the most common radiographic findings [6]. Diffuse pulmonary infiltrates associated with the adult respiratory distress syndrome occur infrequently but are unfortunately associated with a very high mortality rate [7]. Extrapulmonary disease has been described in as many as two-thirds of patients with chronic blastomycosis. In 3 recent clinical studies, however, extrapulmonary disease was found in 25%–40% of patients with blastomycosis [8–10]. The skin, bones, and genitourinary system are the most frequent sites of extrapulmonary disease. Patients frequently present with cutaneous lesions without clinically active pulmonary disease. CNS involvement is rare, except in immunocompromised patients. As many as 40% of patients with AIDS who have blastomycosis have CNS disease, which is manifested as either mass lesions or meningitis [11]. Definitive diagnosis requires the growth of B. dermatitidis from a clinical specimen. Visualization of the characteristic budding yeast form in clinical specimens supports a presumptive diagnosis of blastomycosis and may, in the appropriate clinical setting, prompt the initiation of antifungal therapy. Because they lack both sensitivity and specificity, serological tests are
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blastomycosis in immunocompromised patients.
Pappas, P. G., Threlkeld, M. G., Bedsole, G. D., Cleveland, K. O., Gelfand, M. S., & Dismukes, W. E. (1993) · Medicine · doi:10.1097/00005792-199309000-00003 · Cited by 177
Self-citationEpidemiology of blastomycosis in a region of high endemicity in north central Wisconsin
Baumgardner, D. J., Buggy, B. P., Mattson, B. J., Burdick, J. S., & Ludwig, D. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.4.629 · Cited by 131
Cited by
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Clinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Endemic Mycoses: Blastomycosis, Histoplasmosis, and Sporotrichosis
Kauffman, C. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.002 · Cited by 113
Self-citationThe epidemiology of blastomycosis in Illinois and factors associated with death
Dworkin, M. S., Duckro, A. N., Proia, L., Semel, J. D., & Huhn, G. (2005) · Clinical Infectious Diseases · doi:10.1086/498152 · Cited by 100
Incidence and trends of blastomycosis-associated hospitalizations in the United States.
Seitz, A. E., Younes, N., Steiner, C. A., & Prevots, D. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105466 · Cited by 51
Metadata
- Authors
- Chapman, S. W., Bradsher, R. W., Campbell, G. D., Pappas, P. G., & Kauffman, C. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 679-683
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2095728513
- Cited by
- 220
- References
- 2
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.